X-linked dominant chondrodysplasia, Chassaing-Lacombe type
eks-linkt doh-MIN-uhnt kon-droh-dis-PLAY-zhuh, sha-SANG la-KOHM type
Also known as: Conradi-Hünermann syndrome, CDPX2
At a Glance
What is X-linked dominant chondrodysplasia, Chassaing-Lacombe type?
X-linked dominant chondrodysplasia, Chassaing-Lacombe type, is a rare genetic disorder that primarily affects the skeletal system. It is caused by mutations in the EBP gene, which is responsible for cholesterol metabolism. The condition manifests early, often detectable during prenatal ultrasounds or at birth, with symptoms like limb shortening and skin abnormalities. As the child grows, other symptoms such as cataracts, hearing loss, and spinal deformities may develop. Early symptoms include distinctive facial features and skin lesions, while later symptoms can involve joint pain and limited mobility. Early diagnosis is crucial as it allows for management of symptoms and planning for potential complications. The condition can significantly impact family life, requiring ongoing medical care and support. Prognosis varies, with some individuals leading relatively normal lives, while others may experience severe complications. Daily life for those affected often includes regular medical appointments and therapies to manage symptoms. Despite the challenges, many individuals with this condition can attend school and participate in social activities with appropriate support. Genetic counseling is recommended for families to understand the inheritance pattern and risks for future children.
Medical Definition
X-linked dominant chondrodysplasia, Chassaing-Lacombe type, is a genetic disorder characterized by defective cholesterol biosynthesis due to mutations in the EBP gene. Pathologically, it involves abnormal bone and cartilage development, leading to chondrodysplasia punctata, which is visible as stippling in cartilage and bones on X-rays. Histologically, affected tissues show disrupted endochondral ossification. It is classified under the broader category of chondrodysplasia punctata disorders, specifically as type 2, or CDPX2. Epidemiologically, it is a rare condition with an estimated prevalence of 1 in 100,000. The disease course is variable, with some individuals experiencing mild symptoms, while others may have severe skeletal and systemic manifestations.
X-linked dominant chondrodysplasia, Chassaing-Lacombe type Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Skeletal abnormalities manifest as characteristic stippling of the epiphyses, known as chondrodysplasia punctata. This occurs due to disruptions in cholesterol biosynthesis affecting bone development. Over time, these abnormalities can lead to significant skeletal deformities and growth retardation. Daily life is impacted by mobility issues, and interventions such as physical therapy and orthopedic surgeries can help manage these challenges.
Skin abnormalities present as ichthyosis or scaling, often noticeable at birth or in early infancy. These are caused by defects in cholesterol metabolism affecting skin cell turnover. The condition may persist or worsen with age, leading to discomfort and potential infections. Regular moisturizing and dermatological treatments can alleviate symptoms and improve skin condition.
Craniofacial dysmorphism includes features such as a flat nasal bridge and frontal bossing. These features result from abnormal bone growth due to impaired cholesterol synthesis. As the child grows, these dysmorphic features may become more pronounced, affecting self-esteem and social interactions. Surgical interventions and supportive therapies can help address functional and aesthetic concerns.
Common
Hearing loss can be conductive or sensorineural and is often detected in early childhood. It arises from structural abnormalities in the ear due to disrupted development. Without intervention, hearing loss can progress, impacting language development and communication skills. Hearing aids and early speech therapy can significantly improve outcomes for affected individuals.
Vision problems may include cataracts or other ocular anomalies, presenting in infancy or early childhood. These issues are linked to abnormal cholesterol metabolism affecting eye development. If untreated, vision problems can worsen, leading to impaired visual acuity. Regular ophthalmologic evaluations and corrective lenses or surgery can help manage these conditions.
Developmental delay is often observed in motor and cognitive milestones. This delay is attributed to the overall impact of metabolic disruptions on neurological development. As the child grows, delays may become more evident, affecting educational and social integration. Early intervention programs and tailored educational plans can support developmental progress.
Less Common
Cardiac anomalies, such as septal defects, may be present at birth. These result from disrupted embryonic development due to metabolic abnormalities. Over time, cardiac issues can lead to complications like heart failure if untreated. Regular cardiac monitoring and surgical correction, if necessary, are crucial for managing these anomalies.
Respiratory difficulties can manifest as recurrent respiratory infections or breathing problems. These issues stem from structural anomalies in the respiratory tract and weakened immune response. As the child ages, respiratory problems can lead to chronic lung conditions. Respiratory therapy and vigilant medical care are essential to manage and prevent complications.
What Causes X-linked dominant chondrodysplasia, Chassaing-Lacombe type?
X-linked dominant chondrodysplasia, Chassaing-Lacombe type, is primarily caused by mutations in the EBP gene located on the X chromosome at Xp11.23-p11.22. The EBP gene encodes the emopamil-binding protein, which is crucial for cholesterol biosynthesis as it acts as a sterol isomerase. Mutations in the EBP gene lead to structural changes in the emopamil-binding protein, impairing its ability to catalyze the conversion of sterol intermediates. This disruption results in the accumulation of sterol precursors and a deficiency in downstream cholesterol products within the cell. The imbalance in sterol metabolism affects the integrity of cellular membranes and disrupts lipid rafts, leading to altered signal transduction and membrane dynamics. Organelle dysfunction, particularly in the endoplasmic reticulum, ensues due to the accumulation of misfolded proteins and disrupted lipid homeostasis. Neighboring cells and tissues experience altered intercellular signaling and impaired cellular differentiation, contributing to developmental anomalies. Neuroinflammation may be triggered by the accumulation of toxic sterol intermediates, leading to an immune response that exacerbates tissue damage. Degeneration of white matter and other neural structures occurs due to disrupted cholesterol homeostasis, which is essential for myelin sheath formation and maintenance. Symptoms appear in a specific pattern due to the differential expression of the EBP gene and the varying cholesterol demands of different tissues during development. Disease severity varies between patients due to factors such as the specific mutation type, X-chromosome inactivation patterns in females, and potential modifying genetic or environmental influences.
How is X-linked dominant chondrodysplasia, Chassaing-Lacombe type Diagnosed?
Typical age of diagnosis: X-linked dominant chondrodysplasia, Chassaing-Lacombe type, is typically diagnosed in infancy or early childhood when characteristic skeletal abnormalities become apparent. Diagnosis often occurs following the observation of developmental delays or distinctive physical features during routine pediatric examinations.
Clinicians look for characteristic features such as limb shortening, facial dysmorphisms, and skin abnormalities. A detailed family history is crucial to identify potential X-linked inheritance patterns. Physical examination reveals punctate calcifications and other skeletal anomalies. This step helps direct further diagnostic testing towards confirming chondrodysplasia punctata.
Radiographs are the primary imaging modality used to identify stippled epiphyses and other skeletal abnormalities. These findings confirm the presence of chondrodysplasia punctata and help differentiate it from other skeletal dysplasias. Imaging can exclude conditions like achondroplasia or other forms of skeletal dysplasia. The presence of characteristic calcifications supports the diagnosis of X-linked dominant chondrodysplasia punctata.
Specific laboratory tests include serum calcium and phosphate levels to assess metabolic bone disease. Elevated levels of certain sterols may indicate a defect in cholesterol metabolism. Abnormal results guide the clinician to suspect a genetic etiology. These tests help rule out other metabolic or endocrine disorders that could mimic the condition.
Genetic testing focuses on sequencing the EBP gene, which is known to be involved in this condition. Mutations such as missense or nonsense changes in the EBP gene confirm the diagnosis. Genetic results provide definitive evidence of the condition and inform genetic counseling for the family. This information is crucial for discussing recurrence risks and potential prenatal testing options.
X-linked dominant chondrodysplasia, Chassaing-Lacombe type Treatment Options
Bisphosphonates are used to manage bone density and reduce fracture risk. They work by inhibiting osteoclast-mediated bone resorption. Specific drugs such as alendronate or pamidronate are commonly used. Clinical evidence shows they can improve bone mineral density, but their long-term efficacy in this condition is not well-established. Potential side effects include gastrointestinal discomfort and atypical femoral fractures.
Techniques include range-of-motion exercises and strength training to improve mobility. The goal is to enhance functional ability and reduce discomfort. Sessions are typically conducted 2-3 times per week over several months. Measurable outcomes include improved joint function and reduced pain. Long-term benefits include better quality of life and reduced risk of secondary complications.
Surgery may be indicated for severe skeletal deformities causing functional impairment. Procedures can include osteotomies or spinal fusion to correct alignment. Expected benefits are improved posture and mobility. Surgical risks include infection, nerve damage, and the need for revision surgeries. Post-operative care involves physical therapy and regular follow-up to monitor recovery.
The care team includes geneticists, orthopedic surgeons, physical therapists, and psychologists. Interventions focus on managing symptoms and improving quality of life. Psychosocial support strategies involve counseling and support groups for families. Family education covers condition management and genetic counseling. Long-term monitoring includes regular assessments to adjust care plans as needed.
When to See a Doctor for X-linked dominant chondrodysplasia, Chassaing-Lacombe type
- Severe breathing difficulties — this is an emergency because it may indicate respiratory compromise due to skeletal abnormalities.
- Sudden loss of consciousness — this could be a sign of a severe neurological event or metabolic imbalance.
- Acute chest pain — this may indicate cardiac involvement or severe respiratory distress, requiring immediate evaluation.
- Persistent joint pain — this could signify progressive skeletal issues and should be evaluated by a specialist.
- Delayed developmental milestones — this may indicate neurological or skeletal complications that need further assessment.
- Frequent infections — these may suggest an underlying immune deficiency or structural airway problems that require medical attention.
- Mild skin rashes — monitor for changes in appearance or discomfort, and consult a doctor if they worsen.
- Occasional headaches — keep track of frequency and intensity, and discuss with a healthcare provider if they become more severe.
X-linked dominant chondrodysplasia, Chassaing-Lacombe type — Frequently Asked Questions
Is this condition hereditary?
X-linked dominant chondrodysplasia, Chassaing-Lacombe type, is inherited in an X-linked dominant pattern. This means that a single copy of the altered gene in each cell is sufficient to cause the disorder. Females have a 50% chance of passing the condition to each child, while affected males will pass it to all daughters and no sons. De novo mutations can occur, meaning the condition may appear without a family history. Genetic counseling is recommended to understand the risks and implications for family planning.
What is the life expectancy for someone with this condition?
Life expectancy varies depending on the severity and age of onset of the condition. Early diagnosis and management of complications can improve outcomes. Mortality is often related to respiratory or cardiac complications. Treatment can help manage symptoms and improve quality of life, but may not significantly extend lifespan. Realistic expectations include managing symptoms and improving daily functioning rather than a cure.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves a combination of clinical evaluation, imaging studies, and genetic testing. The time from first symptoms to diagnosis can vary, often taking several months. Specialists such as geneticists, orthopedists, and endocrinologists are usually involved. Delayed diagnosis may occur due to the rarity of the condition and overlapping symptoms with other disorders. Genetic testing confirming mutations in the EBP gene is the definitive diagnostic step.
Are there any new treatments or clinical trials available?
Current research is exploring gene therapy and other novel approaches to manage X-linked dominant chondrodysplasia. ClinicalTrials.gov is a resource for finding ongoing trials related to this condition. Patients should discuss potential participation in trials with their healthcare provider. New treatments are in development, but timelines for availability can be uncertain. It's important to stay informed about emerging research and treatment options.
How does this condition affect daily life and activities?
The condition can significantly impact mobility and self-care due to skeletal abnormalities. Educational support may be necessary for children with developmental delays. Social and emotional challenges are common, requiring psychological support. The family may experience a significant caregiving burden, necessitating external support. Adaptive devices and therapies can help improve independence and quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Hypoparathyroidism and Pseudohypoparathyroidism.
Feingold KR, Adler RA, Ahmed SF et al. · Unknown Journal · 2000 · PMID: 25905388
- 2.Cholesterol metabolism deficiency.
Jira P · Handb Clin Neurol · 2013 · PMID: 23622407
- 3.X-linked dominant chondrodysplasia punctata. Review of literature and report of a case.
Happle R · Hum Genet · 1979 · PMID: 535904
- 4.X-linked dominant chondrodysplasia punctata due to novel mutation in EBP gene: A case report.
Shi X, Lv Y, Jiang Y et al. · Medicine (Baltimore) · 2025 · PMID: 40193659
- 5.X-linked dominant chondrodysplasia punctata with severe phenotype in a female fetus: A case report.
Liu Y, Wang L, Xu B et al. · Medicine (Baltimore) · 2019 · PMID: 30608402
- 6.Sex-linked chondrodysplasia punctata?
Happle R, Matthiass HH, Macher E · Clin Genet · 1977 · PMID: 830452
- 7.Chondrodysplasia punctata: a boy with X-linked recessive chondrodysplasia punctata due to an inherited X-Y translocation with a current classification of these disorders.
Wulfsberg EA, Curtis J, Jayne CH · Am J Med Genet · 1992 · PMID: 1642270
- 8.Spinal deformity in chondrodysplasia punctata.
Mason DE, Sanders JO, MacKenzie WG et al. · Spine (Phila Pa 1976) · 2002 · PMID: 12634559
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-15